Results from CytoDyn’s Pivotal PRO 140 Combination Therapy Trial in HIV to be Presented at ASM Microbe 2018 on June 9
June 04, 2018 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, June 04, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) announced today that results from a Phase 2b/3 trial with PRO 140 (humanized CCR5 monoclonal antibody) in heavily...
Results of CytoDyn’s PRO 140 CD01 Trial and Extension Study Published in HIV Clinical Trials
May 24, 2018 17:00 ET
|
CytoDyn Inc.
Data Provide Support for PRO 140 as long-acting, HIV-1 maintenance therapy VANCOUVER, Washington, May 24, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) announces that results from its CD01...
CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018
April 11, 2018 16:30 ET
|
CytoDyn Inc.
VANCOUVER, Washington, April 11, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing new antibody therapies for combating human immunodeficiency virus (HIV)...
CytoDyn Forms Scientific Advisory Board to Advance PRO 140 Development in Immunological Disorders
March 29, 2018 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, March 29, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) announces the formation of a Scientific Advisory Board to advise on the development of PRO 140 in certain...
CytoDyn to Amend Protocol for PRO 140 Phase 2 Trial in GvHD
March 14, 2018 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, March 14, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing new antibody therapies for combating human immunodeficiency virus (HIV)...
CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection
February 20, 2018 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Feb. 20, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) reports the successful achievement of the primary endpoint in its CD02 Phase 2b/3 pivotal clinical trial with PRO...
Independent Data Monitoring Committee Recommends Continuation of CytoDyn’s PRO 140 Pivotal Combination Therapy Trial as Planned Without Modifications to Achieve Primary Endpoint
December 07, 2017 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Dec. 07, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing new antibody therapies for combating human immunodeficiency virus (HIV)...
CytoDyn’s PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell Transplantation
November 14, 2017 06:00 ET
|
CytoDyn Inc.
PRO 140 Currently in Phase 2 Clinical Trial in Leukemia Patients Receiving Bone Marrow Transplants Preclinical Proof-of-Concept Published in Biology of Blood and Marrow Transplantation VANCOUVER,...
CytoDyn Announces Investment Community Conference Call for October 19, 2017
October 17, 2017 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Oct. 17, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency...
CytoDyn Provides Update on PRO 140 Combination Therapy Pivotal Trial in HIV Patients Following Constructive Meeting With FDA
October 13, 2017 06:00 ET
|
CytoDyn Inc.
Interim efficacy analysis of primary endpoint to be conducted in coming weeks Company to hold investment community conference call on October 19 VANCOUVER, Washington, Oct. 13, 2017 (GLOBE...